Glaukos Corporation (GKOS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Glaukos Corporation (GKOS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

148.27

-3.60 (-2.37%)

At close: Jan 14, 2025, 3:59 PM

149.10

0.56%

Pre-market Jan 15, 2025, 05:34 AM EST

undefined% (undefined)

Bid	128.01
Market Cap	8.18B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.93
PE Ratio (ttm)	-50.6
Forward PE	n/a
Analyst	Strong Buy

Ask	172.17
Volume	533,845
Avg. Volume (20D)	573,296
Open	152.49
Previous Close	151.87
Day's Range	147.21 - 154.76
52-Week Range	83.90 - 161.13
Beta	undefined

About GKOS

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stent...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Jun 25, 2015

Employees 907

Stock Exchange NYSE

Ticker Symbol GKOS

Website https://www.glaukos.com

Analyst Forecast

According to 12 analyst ratings, the average rating for GKOS stock is "Strong Buy." The 12-month stock price forecast is $147, which is a decrease of -0.86% from the latest price.

Buy 83.33%

Hold 8.33%

Sell 8.33%

Stock Forecasts

Next Earnings Release

Glaukos Corporation is scheduled to release its earnings on Feb 19, 2025, during market hours.
Analysts project revenue of $100.72M, reflecting a 22.28% YoY growth and earnings per share of -0.38, making a -39.68% decrease YoY.

Why Price Moved

1 month ago · Source

+4.77%

Glaukos shares are trading higher after Citigroup ... Unlock content with Pro Subscription

2 months ago · Source

-0.3%

Glaukos shares are trading lower. The company reported Q3 financial results.

News

18 hours ago · businesswire.com

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

6 days ago · zacks.com

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

1 week ago · zacks.com

Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?

Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.

2 weeks ago · benzinga.com

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

3 weeks ago · zacks.com

Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA

GKOS announces New Drug Application submission for its Epioxa to the FDA.

3 weeks ago · businesswire.com

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

3 weeks ago · seekingalpha.com

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Glaukos Corporation (GKOS) is well-positioned to grow sales at a CAGR of ~20% to FY'27, potentially hitting $680mm in revenues and $90-$100mm post-tax earnings. The stock is currently valued at 21x sa...

1 month ago · zacks.com

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.

1 month ago · zacks.com

5 Medical Device Stocks That Survived the 2024 Market Volatility

Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.

1 month ago · benzinga.com

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were stron...

1 month ago · zacks.com

Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?

GKOS stock gains from strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.

2 months ago · businesswire.com

Glaukos Announces Participation in Upcoming Investor Conferences

2 months ago · zacks.com

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street esti...

2 months ago · benzinga.com

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Glaukos Corp GKOS reported on Monday third-quarter sales of $96.7 million, up 24% year-over-year, beating the consensus of $91.49 million.

2 months ago · zacks.com

GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.

2 months ago · seekingalpha.com

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Call Start: 16:30 January 1, 0000 5:31 PM ET Glaukos Corporation. (NYSE:GKOS ) Q3 2024 Earnings Conference Call November 04, 2024, 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate A...

2 months ago · zacks.com

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago.

2 months ago · zacks.com

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa

Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.